Hayeshi Rose, Chinyanga Farai, Chengedza Shylet, Mukanganyama Stanley
Biomolecular Interactions Analyses Group, Department of Biochemistry, University of Zimbabwe, Box MP 167, Mount Pleasant, Harare, Zimbabwe.
J Enzyme Inhib Med Chem. 2006 Oct;21(5):581-7. doi: 10.1080/14756360600756105.
Reversal of the drug-resistance phenotype in cancer cells usually involves the use of a chemomodulator that inhibits the function of a resistance-related protein. The aim of this study was to investigate the effects of MDR chemomodulators on human recombinant glutathione S-transferase (GSTs) activity. IC50 values for 15 MDR chemomodulators were determined using 1-chloro-dinitrobenzene (CDNB), cumene hydroproxide (CuOOH) and anticancer drugs as substrates. GSTs A1, P1 and M1 were inhibited by O6-benzylguanine (IC50s around 30 microM), GST P1-1 by sulphinpyrazone (IC50 = 66 microM), GST Al-1 by sulphasalazine, and camptothecin (34 and 74 microM respectively), and GST M1-1 by sulphasalazine, camptothecin and indomethacin (0.3, 29 and 30 microM respectively) using CDNB as a substrate. When ethacrynic acid (for GST P1-1), CuOOH (for A1-1) and 1,3-bis (2-chloroethyl)-1-nitrosourea (for GST M1-1) were used as substrates, these compounds did not significantly inhibit the GST isoforms. However, progesterone was a potent inhibitor of GST P1-1 (IC50 = 1.4 microM) with ethacrynic acid as substrate. These results suggest that the target of chemomodulators in vivo could be a specific resistance-related protein.
癌细胞耐药表型的逆转通常涉及使用一种化学调节剂来抑制耐药相关蛋白的功能。本研究的目的是调查多药耐药(MDR)化学调节剂对人重组谷胱甘肽S-转移酶(GSTs)活性的影响。使用1-氯-二硝基苯(CDNB)、氢过氧化异丙苯(CuOOH)和抗癌药物作为底物,测定了15种MDR化学调节剂的半数抑制浓度(IC50)值。以CDNB为底物时,GSTs A1、P1和M1被O6-苄基鸟嘌呤抑制(IC50约为30 microM),GST P1-1被磺吡酮抑制(IC50 = 66 microM),GST Al-1被柳氮磺胺吡啶和喜树碱抑制(分别为34和74 microM),GST M1-1被柳氮磺胺吡啶、喜树碱和吲哚美辛抑制(分别为0.3、29和30 microM)。当以依他尼酸(用于GST P1-1)、CuOOH(用于A1-1)和1,3-双(2-氯乙基)-1-亚硝基脲(用于GST M1-1)作为底物时,这些化合物并未显著抑制GST同工酶。然而,以依他尼酸为底物时,孕酮是GST P1-1的有效抑制剂(IC50 = 1.4 microM)。这些结果表明,体内化学调节剂的作用靶点可能是一种特定的耐药相关蛋白。